Standard

Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. / Okonechnikov, Konstantin; Federico, Aniello; Schrimpf, Daniel et al.

In: Acta neuropathologica communications, Vol. 11, No. 1, 7, 12.2023, p. 7.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Okonechnikov, K, Federico, A, Schrimpf, D, Sievers, P, Sahm, F, Koster, J, Jones, DTW, von Deimling, A, Pfister, SM, Kool, M & Korshunov, A 2023, 'Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses', Acta neuropathologica communications, vol. 11, no. 1, 7, pp. 7. https://doi.org/10.1186/s40478-023-01504-1

APA

Okonechnikov, K., Federico, A., Schrimpf, D., Sievers, P., Sahm, F., Koster, J., Jones, D. T. W., von Deimling, A., Pfister, S. M., Kool, M., & Korshunov, A. (2023). Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. Acta neuropathologica communications, 11(1), 7. [7]. https://doi.org/10.1186/s40478-023-01504-1

Vancouver

Okonechnikov K, Federico A, Schrimpf D, Sievers P, Sahm F, Koster J et al. Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. Acta neuropathologica communications. 2023 Dec;11(1):7. 7. doi: 10.1186/s40478-023-01504-1

Author

Okonechnikov, Konstantin ; Federico, Aniello ; Schrimpf, Daniel et al. / Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. In: Acta neuropathologica communications. 2023 ; Vol. 11, No. 1. pp. 7.

BibTeX

@article{6e85d0dbb10d44eb866c448c82ca306c,
title = "Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses",
abstract = "Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with up to 80% success rate. However, disease relapses occur in approximately 30% of patients and successful salvage treatment strategies at relapse remain scarce. Acquired copy number changes or TP53 mutations are known to occur frequently in relapses, while methylation profiles usually remain highly similar to those of the matching primary tumors, indicating that in general molecular subgrouping does not change during the course of the disease. In the current study, we have used RNA sequencing data to analyze the transcriptome profiles of 43 primary-relapse MB pairs in order to identify specific molecular features of relapses within various tumor groups. Gene variance analysis between primary and relapse samples demonstrated the impact of age in SHH-MB: the changes in gene expression relapse profiles were more pronounced in the younger patients (< 10 years old), which were also associated with increased DNA aberrations and somatic mutations at relapse probably driving this effect. For Group 3/4 MB transcriptome data analysis uncovered clear sets of genes either active or decreased at relapse that are significantly associated with survival, thus could be potential predictive markers. In addition, deconvolution analysis of bulk transcriptome data identified progression-associated differences in cell type enrichment. The proportion of undifferentiated progenitors increased in SHH-MB relapses with a concomitant decrease of differentiated neuron-like cells, while in Group 3/4 MB relapses cell cycle activity increases and differentiated neuron-like cells proportion decreases as well. Thus, our findings uncovered significant transcriptome changes in the molecular signatures of relapsed MB and could be potentially useful for further clinical purposes.",
keywords = "Medulloblastoma, Prognosis, Relapses, Transcriptomics",
author = "Konstantin Okonechnikov and Aniello Federico and Daniel Schrimpf and Philipp Sievers and Felix Sahm and Jan Koster and Jones, {David T. W.} and {von Deimling}, Andreas and Pfister, {Stefan M.} and Marcel Kool and Andrey Korshunov",
note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = dec,
doi = "10.1186/s40478-023-01504-1",
language = "English",
volume = "11",
pages = "7",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central",
number = "1",

}

RIS

TY - JOUR

T1 - Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses

AU - Okonechnikov, Konstantin

AU - Federico, Aniello

AU - Schrimpf, Daniel

AU - Sievers, Philipp

AU - Sahm, Felix

AU - Koster, Jan

AU - Jones, David T. W.

AU - von Deimling, Andreas

AU - Pfister, Stefan M.

AU - Kool, Marcel

AU - Korshunov, Andrey

N1 - Publisher Copyright: © 2023, The Author(s).

PY - 2023/12

Y1 - 2023/12

N2 - Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with up to 80% success rate. However, disease relapses occur in approximately 30% of patients and successful salvage treatment strategies at relapse remain scarce. Acquired copy number changes or TP53 mutations are known to occur frequently in relapses, while methylation profiles usually remain highly similar to those of the matching primary tumors, indicating that in general molecular subgrouping does not change during the course of the disease. In the current study, we have used RNA sequencing data to analyze the transcriptome profiles of 43 primary-relapse MB pairs in order to identify specific molecular features of relapses within various tumor groups. Gene variance analysis between primary and relapse samples demonstrated the impact of age in SHH-MB: the changes in gene expression relapse profiles were more pronounced in the younger patients (< 10 years old), which were also associated with increased DNA aberrations and somatic mutations at relapse probably driving this effect. For Group 3/4 MB transcriptome data analysis uncovered clear sets of genes either active or decreased at relapse that are significantly associated with survival, thus could be potential predictive markers. In addition, deconvolution analysis of bulk transcriptome data identified progression-associated differences in cell type enrichment. The proportion of undifferentiated progenitors increased in SHH-MB relapses with a concomitant decrease of differentiated neuron-like cells, while in Group 3/4 MB relapses cell cycle activity increases and differentiated neuron-like cells proportion decreases as well. Thus, our findings uncovered significant transcriptome changes in the molecular signatures of relapsed MB and could be potentially useful for further clinical purposes.

AB - Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with up to 80% success rate. However, disease relapses occur in approximately 30% of patients and successful salvage treatment strategies at relapse remain scarce. Acquired copy number changes or TP53 mutations are known to occur frequently in relapses, while methylation profiles usually remain highly similar to those of the matching primary tumors, indicating that in general molecular subgrouping does not change during the course of the disease. In the current study, we have used RNA sequencing data to analyze the transcriptome profiles of 43 primary-relapse MB pairs in order to identify specific molecular features of relapses within various tumor groups. Gene variance analysis between primary and relapse samples demonstrated the impact of age in SHH-MB: the changes in gene expression relapse profiles were more pronounced in the younger patients (< 10 years old), which were also associated with increased DNA aberrations and somatic mutations at relapse probably driving this effect. For Group 3/4 MB transcriptome data analysis uncovered clear sets of genes either active or decreased at relapse that are significantly associated with survival, thus could be potential predictive markers. In addition, deconvolution analysis of bulk transcriptome data identified progression-associated differences in cell type enrichment. The proportion of undifferentiated progenitors increased in SHH-MB relapses with a concomitant decrease of differentiated neuron-like cells, while in Group 3/4 MB relapses cell cycle activity increases and differentiated neuron-like cells proportion decreases as well. Thus, our findings uncovered significant transcriptome changes in the molecular signatures of relapsed MB and could be potentially useful for further clinical purposes.

KW - Medulloblastoma

KW - Prognosis

KW - Relapses

KW - Transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=85146194845&partnerID=8YFLogxK

U2 - 10.1186/s40478-023-01504-1

DO - 10.1186/s40478-023-01504-1

M3 - Article

C2 - 36635768

VL - 11

SP - 7

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

IS - 1

M1 - 7

ER -

ID: 31293265